Dermatology

Deucravacitinib (Sotyktu) also demonstrates improvements in signs and symptoms, extra-articular manifestations, and patient-reported outcomes.

Patients aged 12 to under 18 saw clinically meaningful regrowth on the scalp, eyebrow, and eyelashes with both high-dose and low-dose treatment.

Investigators note that low itch and mild disease severity are maintained following a treatment-free interval of 80 days.

The ADjoin long-term extensive study is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis.

Investigators report that the safety profile is also similar between both drugs.

The FDA initially approved deucravacitinib (Sotyktu) in September 2022 to treat moderate-to-severe plaque psoriasis.

For patients with atopic dermatitis reporting moderate-to-severe scratching, researchers explored the efficacy of an AI-enabled wearable sensor with closed-loop haptic feedback.

Data from a previous phase 1b trial show improvements in the Eczema Area and Severity Index (EASI)-75 compared with the placebo at 12 weeks.

Researchers conducted a literature review of patients’ clinical experiences with using secukinumab to treat psoriatic arthritis.

Vtama from Organon was previously approved in May 2022 to treat plaque psoriasis in adults.

FDA approval was granted on September 13, 2024.

The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.

“Emrosi has potential to become the best-in-class oral medication to treat the condition,” said the CEO of Journey Medical.

Research presented at AMCP Nexus 2024 underscored and explored the need for treatments that can prevent or mitigate flare-ups in patients with AD.

The monoclonal antibody was also approved for active non-radiographic axial spondyloarthritis and active ankylosing spondylitis.

LEO Pharma expects the regulatory review process to be completed in the second half of 2025.

Lebrikizumab-lbks is a targeted treatment that addresses the root cause of atopic dermatitis; by reducing inflammation throughout the body, it can help alleviate the dry, itchy, and irritated skin that often characterizes the condition.

LEO Pharma presented data from 2 of the largest multinational real-world studies on the prevalence, severity and treatment of chronic hand eczema at the European Society of Contact Dermatitis congress.

Results from the INTEGUMENT-OLE phase 3 trial showed the therapy was also well-tolerated, with no new safety signals observed during treatment of up to 56 weeks.

The approval of apremilast to treat plaque psoriasis in children and adolescents aged 6 years and older was based on data from the phase 3 SPROUT trial.

Izokibep from Affibody is a small therapeutic protein designed to inhibit IL-17A.

Two phase 3 trials evaluating nemolizumab found that 41% of patients treated with the therapy achieved at least a 4-point reduction in itch intensity at week 16.

Researchers addressed the difference between prescribing guselkumab doses every 16 weeks and every 8 weeks for super responder patients with moderate to severe psoriasis.

Pharmacists should be knowledgeable about the symptoms of chemical peel irritation to effectively advise patients.

Catch up on important dermatology news from the month of July.

Galderma said the FDA has accepted the company’s Biologics License Application for the therapy based on data from the trials.

The most common adverse events in patients using oral corticosteroids for more than 90 days included fracture, hyperlipidemia, myocardial infarction, and avascular necrosis.

Delgocitinib cream from LEO Pharmaceuticals showed superior efficacy compared to cream vehicle and was well tolerated over 16 weeks.

Patients with acne who adhered to a mediterranean diet and supplemented with omega-3s saw improvements in inflammatory and non-inflammatory lesions.

Researchers aimed to address the extent of stigmatization’s effect on the mental health of adolescents with chronic skin disorders.